Loading...

Medical Developments International

ASX:MVP
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MVP
ASX
A$347M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment in Australia and internationally. The last earnings update was 63 days ago. More info.


Add to Portfolio Compare Print
  • Medical Developments International has significant price volatility in the past 3 months.
MVP Share Price and Events
7 Day Returns
-1.5%
ASX:MVP
2.1%
AU Pharmaceuticals
-0%
AU Market
1 Year Returns
-22.5%
ASX:MVP
-21.1%
AU Pharmaceuticals
4.6%
AU Market
MVP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medical Developments International (MVP) -1.5% 21.1% 33.4% -22.5% -11.1% 302.3%
AU Pharmaceuticals 2.1% 10.2% -4.8% -21.1% -31.8% -19.1%
AU Market -0% 1% 6.9% 4.6% 18.2% 4.8%
1 Year Return vs Industry and Market
  • MVP underperformed the Pharmaceuticals industry which returned -21.1% over the past year.
  • MVP underperformed the Market in Australia which returned 4.6% over the past year.
Price Volatility
MVP
Industry
5yr Volatility vs Market

MVP Value

 Is Medical Developments International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Medical Developments International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Medical Developments International.

ASX:MVP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:MVP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 30%) (0.08%))
0.821
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.821 * 5.96%)
7.21%

Discounted Cash Flow Calculation for ASX:MVP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Medical Developments International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:MVP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 7.21%)
2019 9.40 Analyst x2 8.77
2020 -9.80 Analyst x2 -8.53
2021 4.40 Analyst x1 3.57
2022 2.74 Est @ -37.8% 2.07
2023 2.03 Est @ -25.77% 1.43
2024 1.68 Est @ -17.34% 1.11
2025 1.49 Est @ -11.45% 0.91
2026 1.38 Est @ -7.32% 0.79
2027 1.32 Est @ -4.43% 0.70
2028 1.29 Est @ -2.41% 0.64
Present value of next 10 years cash flows A$11.47
ASX:MVP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$1.29 × (1 + 2.31%) ÷ (7.21% – 2.31%)
A$26.87
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$26.87 ÷ (1 + 7.21%)10
A$13.40
ASX:MVP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$11.47 + A$13.40
A$24.87
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$24.87 / 65.52
A$0.38
ASX:MVP Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.38
Current discount Discount to share price of A$5.27
= -1 x (A$5.27 - A$0.38) / A$0.38
-1288%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Medical Developments International is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medical Developments International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medical Developments International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:MVP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.00
ASX:MVP Share Price ** ASX (2019-04-23) in AUD A$5.27
Australia Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 20.76x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medical Developments International.

ASX:MVP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MVP Share Price ÷ EPS (both in AUD)

= 5.27 ÷ 0.00

1280.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Developments International is overvalued based on earnings compared to the AU Pharmaceuticals industry average.
  • Medical Developments International is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Medical Developments International's expected growth come at a high price?
Raw Data
ASX:MVP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1280.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
101.9%per year
Global Pharmaceuticals Industry PEG Ratio Median Figure of 120 Publicly-Listed Pharmaceuticals Companies 1.48x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

ASX:MVP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 1280.99x ÷ 101.9%

12.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Developments International is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Medical Developments International's assets?
Raw Data
ASX:MVP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.70
ASX:MVP Share Price * ASX (2019-04-23) in AUD A$5.27
Australia Pharmaceuticals Industry PB Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 3.06x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:MVP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MVP Share Price ÷ Book Value per Share (both in AUD)

= 5.27 ÷ 0.70

7.51x

* Primary Listing of Medical Developments International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Developments International is overvalued based on assets compared to the AU Pharmaceuticals industry average.
X
Value checks
We assess Medical Developments International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Medical Developments International has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MVP Future Performance

 How is Medical Developments International expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
101.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medical Developments International expected to grow at an attractive rate?
  • Medical Developments International's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Medical Developments International's earnings growth is expected to exceed the Australia market average.
  • Medical Developments International's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:MVP Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:MVP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 101.9%
ASX:MVP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 28.1%
Australia Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 55.6%
Australia Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 29.2%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:MVP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:MVP Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 36 10 6 2
2020-06-30 26 9 3 2
2019-06-30 20 21 1 2
ASX:MVP Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 19 23 0
2018-09-30 18 12 0
2018-06-30 17 2 0
2018-03-31 18 2 1
2017-12-31 18 3 2
2017-09-30 18 3 2
2017-06-30 18 4 2
2017-03-31 18 4 2
2016-12-31 18 4 2
2016-09-30 17 8 2
2016-06-30 15 12 2
2016-03-31 14 12 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medical Developments International's earnings are expected to grow significantly at over 20% yearly.
  • Medical Developments International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:MVP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Medical Developments International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MVP Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.08 0.09 0.08 2.00
2020-06-30 0.04 0.05 0.03 2.00
2019-06-30 0.01 0.01 0.01 2.00
ASX:MVP Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.01
2017-12-31 0.03
2017-09-30 0.03
2017-06-30 0.03
2017-03-31 0.03
2016-12-31 0.03
2016-09-30 0.03
2016-06-30 0.03
2016-03-31 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Medical Developments International is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Medical Developments International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medical Developments International has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MVP Past Performance

  How has Medical Developments International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medical Developments International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medical Developments International's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Medical Developments International's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Medical Developments International's 1-year earnings growth is negative, it can't be compared to the Global Pharmaceuticals industry average.
Earnings and Revenue History
Medical Developments International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medical Developments International Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MVP Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 19.18 0.25 9.68
2018-09-30 18.32 0.25 9.50
2018-06-30 17.46 0.24 9.33
2018-03-31 17.78 0.89 8.79
2017-12-31 18.10 1.54 8.26
2017-09-30 18.22 1.68 8.13
2017-06-30 18.35 1.82 8.01
2017-03-31 17.94 1.78 7.61
2016-12-31 17.53 1.74 7.21
2016-09-30 16.50 1.66 6.92
2016-06-30 15.47 1.57 6.64
2016-03-31 13.78 1.30 5.79
2015-12-31 12.10 1.03 4.94
2015-09-30 11.85 1.28 4.56
2015-06-30 11.61 1.53 4.18
2015-03-31 10.97 1.35 4.27
2014-12-31 10.33 1.18 4.36
2014-09-30 9.85 1.03 4.28
2014-06-30 9.37 0.88 4.21
2014-03-31 9.58 1.08 4.03
2013-12-31 9.79 1.29 3.85
2013-09-30 10.76 1.80 3.84
2013-06-30 11.73 2.31 3.82
2013-03-31 12.13 2.65 3.83
2012-12-31 12.53 2.99 3.84
2012-09-30 11.92 2.85 3.57
2012-06-30 11.31 2.70 3.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Medical Developments International has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Medical Developments International used its assets less efficiently than the AU Pharmaceuticals industry average last year based on Return on Assets.
  • Medical Developments International's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Medical Developments International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medical Developments International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MVP Health

 How is Medical Developments International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medical Developments International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medical Developments International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medical Developments International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medical Developments International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 143.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medical Developments International Company Filings, last reported 3 months ago.

ASX:MVP Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 44.09 0.27 32.27
2018-09-30 44.09 0.27 32.27
2018-06-30 21.04 9.25 0.79
2018-03-31 21.04 9.25 0.79
2017-12-31 21.35 3.92 0.91
2017-09-30 21.35 3.92 0.91
2017-06-30 21.60 0.43 1.69
2017-03-31 21.60 0.43 1.69
2016-12-31 20.84 0.46 5.53
2016-09-30 20.84 0.46 5.53
2016-06-30 19.03 0.48 5.62
2016-03-31 19.03 0.48 5.62
2015-12-31 17.64 0.89 9.55
2015-09-30 17.64 0.89 9.55
2015-06-30 17.41 1.11 0.95
2015-03-31 17.41 1.11 0.95
2014-12-31 16.58 1.58 0.60
2014-09-30 16.58 1.58 0.60
2014-06-30 15.82 3.66 1.66
2014-03-31 15.82 3.66 1.66
2013-12-31 15.36 3.37 1.09
2013-09-30 15.36 3.37 1.09
2013-06-30 15.73 1.44 0.77
2013-03-31 15.73 1.44 0.77
2012-12-31 16.64 0.00 2.13
2012-09-30 16.64 0.00 2.13
2012-06-30 16.17 0.00 3.48
  • Medical Developments International's level of debt (0.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (21.9% vs 0.6% today).
  • Debt is well covered by operating cash flow (8490.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 13.1x coverage).
X
Financial health checks
We assess Medical Developments International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medical Developments International has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MVP Dividends

 What is Medical Developments International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.76%
Current annual income from Medical Developments International dividends. Estimated to be 0.76% next year.
If you bought A$2,000 of Medical Developments International shares you are expected to receive A$15 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Medical Developments International's pays a lower dividend yield than the bottom 25% of dividend payers in Australia (2.52%).
  • Medical Developments International's dividend is below the markets top 25% of dividend payers in Australia (5.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:MVP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 140 Stocks 3%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:MVP Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30 0.04 2.00
2020-06-30 0.04 2.00
2019-06-30 0.04 2.00
ASX:MVP Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2019-02-19 0.040 0.880
2018-08-16 0.040 0.960
2018-02-16 0.040 0.653
2017-08-17 0.040 0.648
2017-02-20 0.040 0.797
2016-08-17 0.040 0.810
2016-02-17 0.040 0.717
2015-02-19 0.000 0.000
2014-08-21 0.000 0.000
2014-02-21 0.000 0.000
2013-08-23 0.040 3.102
2013-02-22 0.060 4.119
2012-08-22 0.060 3.890
2012-02-23 0.060 8.070
2011-08-29 0.030 5.721

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medical Developments International is not paying a notable dividend for Australia, therefore no need to check if the payments are stable.
  • Medical Developments International is not paying a notable dividend for Australia, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Medical Developments International's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Medical Developments International's dividends as it is not paying a notable one for Australia.
Future Payout to shareholders
  • No need to calculate the sustainability of Medical Developments International's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Medical Developments International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medical Developments International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medical Developments International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MVP Management

 What is the CEO of Medical Developments International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Sharman
COMPENSATION A$447,351
AGE 52
TENURE AS CEO 9 years
CEO Bio

Mr. John Stewart Sharman, M.App.Fin, CA, B Ec, has been the Chief Executive Officer of Medical Developments International Limited since April 12, 2010. Mr. Sharman serves as Investment Director of CVC Venture Managers Pty Limited. He served as a Managing Director of Cyclopharm Ltd., from September 1, 2006 to June 3, 2008. He held leadership roles of Vita Life Sciences Ltd from 2003 to 2006 and Cyclopharm Ltd from 2003 to 2008. He served as a Finance Director of Vita Life Sciences Ltd., from October 2003 to August 2006 and also served as its Company Secretary. Mr. Sharman has over 20 years experience in company management, private equity, investment banking and corporate finance. He has extensive experience in capital raisings, negotiation of key agreements, recovery and commercial strategies for performing and non performing companies in all stages of company development. He has extensive distribution networks within the medical equipment, pharmaceutical and financial industries globally, including developed and emerging markets. He served as an Executive Director of Cyclopharm Ltd. until February 29, 2012. He served as a Non Executive Director of Vita Life Sciences Ltd. until July 26, 2012. He served as a Director of Cyclopharm Ltd. from November 21, 2005 to June 3, 2008. He served as an Executive Director of Vita Life Sciences Ltd., from October 2003 to August 2006 and previously since May 31, 2002. Mr. Sharman holds Master of Applied Finance, Macquarie University, NSW and a Bachelor of Economics Degreefrom Monash University, Victoria and an Associate of the Institute of Chartered Accountants.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year.
  • John's remuneration is lower than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Medical Developments International management team in years:

1.1
Average Tenure
  • The average tenure for the Medical Developments International management team is less than 2 years, this suggests a new team.
Management Team

John Sharman

TITLE
Chief Executive Officer
COMPENSATION
A$447K
AGE
52
TENURE
9 yrs

Mark Edwards

TITLE
CFO & Company Secretary
COMPENSATION
A$192K
TENURE
1.5 yrs

Scott Courtney

TITLE
Director of Research & Operations
TENURE
3.3 yrs

Michelle Bradney

TITLE
Head of Medical Affairs
TENURE
0.7 yrs

Wai Chi

TITLE
Head of Regulatory Affairs
TENURE
0.4 yrs

Neil Issa

TITLE
Head of Quality
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the Medical Developments International board of directors in years:

6
Average Tenure
  • The tenure for the Medical Developments International board of directors is about average.
Board of Directors

David Williams

TITLE
Non-Executive Chairman
COMPENSATION
A$75K
AGE
54
TENURE
15.6 yrs

Philip Powell

TITLE
Non-Executive Director
COMPENSATION
A$45K
AGE
61
TENURE
4.3 yrs

R. Johnston

TITLE
Non-Executive Director
COMPENSATION
A$45K
TENURE
6.4 yrs

Leon Hoare

TITLE
Non-Executive Director
COMPENSATION
A$45K
TENURE
5.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Medical Developments International insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
25. Feb 19 Buy R. Johnston Individual 22. Feb 19 25. Feb 19 5,000 A$3.75 A$18,710
26. Dec 18 Buy M&G Investment Management Limited Company 22. Aug 18 20. Dec 18 321,609 A$3.97 A$1,236,693
20. Dec 18 Buy David Williams Individual 18. Dec 18 19. Dec 18 34,246 A$3.70 A$126,261
18. May 18 Buy David Williams Individual 17. May 18 18. May 18 288,991 A$5.81 A$1,615,941
15. May 18 Buy David Williams Individual 15. May 18 15. May 18 225,258 A$5.96 A$1,341,659
14. May 18 Buy David Williams Individual 14. May 18 14. May 18 235,751 A$6.21 A$1,464,061
X
Management checks
We assess Medical Developments International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medical Developments International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MVP News

Simply Wall St News

Should You Be Concerned About Medical Developments International Limited's (ASX:MVP) ROE?

We'll use ROE to examine Medical Developments International Limited (ASX:MVP), by way of a worked example. … Medical Developments International has a ROE of 1.2%, based on the last twelve months. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

What Investors Should Know About Medical Developments International Limited's (ASX:MVP) Financial Strength

Investors are always looking for growth in small-cap stocks like Medical Developments International Limited (ASX:MVP), with a market cap of AU$336.69m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Medical Developments International Limited (ASX:MVP): Does The -11.82% Earnings Drop Reflect A Longer Term Trend?

Investors with a long-term horizong may find it valuable to assess Medical Developments International Limited's (ASX:MVP) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. … For Medical Developments International, its most recent earnings (trailing twelve month) is AU$1.54M, which, in comparison to the prior year's level, has dropped by -11.82%. … This means Medical Developments International has been growing expenses, which is hurting margins and earnings, and is not a sustainable practice.

Simply Wall St -

What You Must Know About Medical Developments International Limited's (ASX:MVP) Return on Equity

See our latest analysis for Medical Developments International Breaking down ROE — the mother of all ratios Firstly, Return on Equity, or ROE, is simply the percentage of last years’ earning against the book value of shareholders’ equity. … For now, let’s just look at the cost of equity number for Medical Developments International, which is 8.55%. … Since Medical Developments International’s return does not cover its cost, with a difference of -1.35%, this means its current use of equity is not efficient and not sustainable.

Simply Wall St -

What does Medical Developments International Limited's (ASX:MVP) Balance Sheet Tell Us Abouts Its Future?

How does MVP’s operating cash flow stack up against its debt? … Additionally, MVP has produced A$4.0M in operating cash flow during the same period of time, resulting in an operating cash to total debt ratio of 934.97%, indicating that MVP’s operating cash is sufficient to cover its debt. … MVP has demonstrated its ability to generate sufficient levels of cash flow, while its debt hovers at a safe level.

Simply Wall St -

Medical Developments International Limited (ASX:MVP): What's The Analyst Consensus Outlook?

In June 2017, Medical Developments International Limited (ASX:MVP) released its latest earnings announcement, which signalled that the business benefited from a robust tailwind, eventuating to a double-digit earnings growth of 16.00%. … Investors may find it useful to understand how market analysts view Medical Developments International's earnings growth trajectory over the next couple of years and whether the future looks even brighter than the past. … This means that, we can presume Medical Developments International will grow its earnings by 65.45% every year for the next couple of years.

Simply Wall St -

November Growth Opportunities – Medical Developments International And More

ASX:MVP Future Profit Nov 23rd 17 Corporate Travel Management Limited (ASX:CTD) Corporate Travel Management Limited, a travel management solutions company, manages the purchase and delivery of travel services for the corporate market worldwide. … ASX:CTD Future Profit Nov 23rd 17 GR Engineering Services Limited (ASX:GNG) GR Engineering Services Limited, an engineering, consulting, and contracting company, provides engineering design and construction services to the mining and mineral processing industries in Australia and internationally. … ASX:GNG Future Profit Nov 23rd 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

How Does Medical Developments International Limited's (ASX:MVP) EPS Growth Stack Up Against Industry Performance?

This means on average, Medical Developments International has been able to gradually raise its net income over the past few years as well. … Though Medical Developments International's past data is helpful, it is only one aspect of my investment thesis. … I recommend you continue to research Medical Developments International to get a better picture of the stock by looking at: 1.

Simply Wall St -

What Should We Expect From Medical Developments International Limited's (ASX:MVP) Earnings Over The Next Year?

Based on the latest analyst prediction, Medical Developments International Limited (ASX:MVP) is estimated to optimistically grow its earnings by over 300% in the upcoming three years. … Medical Developments International's extremely high growth potential in the near future is attracting investors. … Although its past performance is not supportive of a positive growth trend, it could also mean MVP is growing off a lower base, meaning a higher growth rate is easier to achieve.

Simply Wall St -

Financially Strong And High Growth Stocks

In terms of profitability and returns, stocks such as Medical Developments International and Mainstream Group Holdings are expected to outperform its peers in the future. … ASX:MVP Future Profit Oct 23rd 17 Mainstream Group Holdings Limited (ASX:MAI) Mainstream Group Holdings Limited provides fund administration services for the financial services industry in the Asia Pacific, the United States, and Europe. … ASX:MAI Future Profit Oct 23rd 17 Corporate Travel Management Limited (ASX:CTD) Corporate Travel Management Limited, a travel management solutions company, manages the purchase and delivery of travel services for the corporate market worldwide.

Simply Wall St -

MVP Company Info

Description

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment in Australia and internationally. The company operates in three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management; Penthrox, a prescription only medicine for acute pain; medical devices; and various veterinary anesthetic machines to veterinarians. Medical Developments International Limited is headquartered in Scoresby, Australia.

Details
Name: Medical Developments International Limited
MVP
Exchange: ASX
Founded:
A$347,238,753
65,516,746
Website: http://www.medicaldev.com
Address: Medical Developments International Limited
4 Caribbean Drive,
Scoresby,
Victoria, 3179,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MVP Ordinary Shares Australian Securities Exchange AU AUD 15. Dec 2003
CHIA MVP Ordinary Shares Chi-X Australia AU AUD 15. Dec 2003
Number of employees
Current staff
Staff numbers
55
Medical Developments International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 10:32
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/02/26
Last earnings filing: 2019/02/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.